Iovance Biotherapeutics

IOVA Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$3.43

-0.58% today

52W: $1.64 – $5.63

52W Low: $1.64 Position: 44.9% 52W High: $5.63

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

5.36x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.4B

Market Capitalization

Revenue Growth

17.7%

YoY Revenue Growth

Profit Margin

-148.38%

Net profit margin

ROE

-55.5%

Return on Equity

Beta

0.76

Market sensitivity

Short Interest

30.05%

% of float sold short

Avg. Volume

14,937,663

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

10 analysts

Avg. Price Target

$9.00

+162.39% upside

Target Range

$4.00 – $16.00

About the Company

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 975 Exchange: NGM